These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 27909582)
1. Ebola research funding: a systematic analysis, 1997-2015. Fitchett JR; Lichtman A; Soyode DT; Low A; Villar de Onis J; Head MG; Atun R J Glob Health; 2016 Dec; 6(2):020703. PubMed ID: 27909582 [TBL] [Abstract][Full Text] [Related]
2. Knowledge and attitude towards Ebola and Marburg virus diseases in Uganda using quantitative and participatory epidemiology techniques. Nyakarahuka L; Skjerve E; Nabadda D; Sitali DC; Mumba C; Mwiine FN; Lutwama JJ; Balinandi S; Shoemaker T; Kankya C PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005907. PubMed ID: 28892520 [TBL] [Abstract][Full Text] [Related]
3. [Marburg and Ebola hemorrhagic fevers--pathogens, epidemiology and therapy]. Stock I Med Monatsschr Pharm; 2014 Sep; 37(9):324-30; quiz 331-2. PubMed ID: 25282746 [TBL] [Abstract][Full Text] [Related]
4. Sequencing ebola and marburg viruses genomes using microarrays. Hardick J; Woelfel R; Gardner W; Ibrahim S J Med Virol; 2016 Aug; 88(8):1303-8. PubMed ID: 26822839 [TBL] [Abstract][Full Text] [Related]
5. Catching Chances: The Movement to Be on the Ground and Research Ready before an Outbreak. Brett-Major D; Lawler J Viruses; 2018 Aug; 10(8):. PubMed ID: 30126221 [TBL] [Abstract][Full Text] [Related]
6. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Bausch DG; Sprecher AG; Jeffs B; Boumandouki P Antiviral Res; 2008 Apr; 78(1):150-61. PubMed ID: 18336927 [TBL] [Abstract][Full Text] [Related]
7. Lessons learned during active epidemiological surveillance of Ebola and Marburg viral hemorrhagic fever epidemics in Africa. Allaranga Y; Kone ML; Formenty P; Libama F; Boumandouki P; Woodfill CJ; Sow I; Duale S; Alemu W; Yada A East Afr J Public Health; 2010 Mar; 7(1):30-6. PubMed ID: 21413569 [TBL] [Abstract][Full Text] [Related]
8. Drug targets in infections with Ebola and Marburg viruses. Gene OG; Julia BE; Vanessa MR; Victoria WJ; Thomas GW; Lisa HE Infect Disord Drug Targets; 2009 Apr; 9(2):191-200. PubMed ID: 19275706 [TBL] [Abstract][Full Text] [Related]
9. Ebola and Marburg viruses: pathogenesis and development of countermeasures. Hensley LE; Jones SM; Feldmann H; Jahrling PB; Geisbert TW Curr Mol Med; 2005 Dec; 5(8):761-72. PubMed ID: 16375711 [TBL] [Abstract][Full Text] [Related]
10. The allocation of USdollar;105 billion in global funding from G20 countries for infectious disease research between 2000 and 2017: a content analysis of investments. Head MG; Brown RJ; Newell ML; Scott JAG; Batchelor J; Atun R Lancet Glob Health; 2020 Oct; 8(10):e1295-e1304. PubMed ID: 32971052 [TBL] [Abstract][Full Text] [Related]
11. Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates. Suschak JJ; Schmaljohn CS Hum Vaccin Immunother; 2019; 15(10):2359-2377. PubMed ID: 31589088 [TBL] [Abstract][Full Text] [Related]
12. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Leroy EM; Gonzalez JP; Baize S Clin Microbiol Infect; 2011 Jul; 17(7):964-76. PubMed ID: 21722250 [TBL] [Abstract][Full Text] [Related]
13. Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo. Pessi A; Bixler SL; Soloveva V; Radoshitzky S; Retterer C; Kenny T; Zamani R; Gomba G; Gharabeih D; Wells J; Wetzel KS; Warren TK; Donnelly G; Van Tongeren SA; Steffens J; Duplantier AJ; Kane CD; Vicat P; Couturier V; Kester KE; Shiver J; Carter K; Bavari S Antiviral Res; 2019 Nov; 171():104592. PubMed ID: 31473342 [TBL] [Abstract][Full Text] [Related]